MDxHealth (NASDAQ:MDXH) Shares Up 2.6%

Shares of MDxHealth SA (NASDAQ:MDXH) shot up 2.6% during trading on Thursday . The company traded as high as $2.39 and last traded at $2.33. 8,011 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 27,520 shares. The stock had previously closed at $2.27.

Analysts Set New Price Targets

A number of research firms recently issued reports on MDXH. Piper Sandler raised their price objective on shares of MDxHealth from $6.00 to $7.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. BTIG Research raised their price objective on shares of MDxHealth from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, March 7th. Finally, William Blair reissued an “outperform” rating on shares of MDxHealth in a report on Thursday, March 7th.

MDxHealth Trading Up 2.6 %

The company has a quick ratio of 1.53, a current ratio of 1.69 and a debt-to-equity ratio of 5.43. The business’s fifty day moving average is $2.73 and its 200-day moving average is $4.99.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Wednesday, May 1st. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.01). The business had revenue of $19.83 million for the quarter, compared to analyst estimates of $18.32 million. On average, equities research analysts predict that MDxHealth SA will post -1 earnings per share for the current year.

Hedge Funds Weigh In On MDxHealth

Several large investors have recently added to or reduced their stakes in the company. FAS Wealth Partners Inc. purchased a new position in MDxHealth during the first quarter valued at approximately $42,000. MVM Partners LLC purchased a new position in MDxHealth during the fourth quarter valued at approximately $17,906,000. Finally, Perkins Capital Management Inc. lifted its holdings in shares of MDxHealth by 2.7% in the fourth quarter. Perkins Capital Management Inc. now owns 415,225 shares of the company’s stock worth $1,636,000 after buying an additional 11,000 shares in the last quarter.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.